ALNFL — Nfl Biosciences SAS Balance Sheet
0.000.00%
- €14.19m
- €11.09m
Annual balance sheet for Nfl Biosciences SAS, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | FAS | FAS | FAS | FAS | FAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.31 | 3.2 | 1.21 | 2.53 | 2.11 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.156 | 0.22 | 0.742 | 1.11 | 1.06 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.468 | 3.56 | 2.26 | 3.82 | 3.34 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0 | 0.002 | 0.002 | 0.009 | 0.125 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 0.577 | 3.69 | 2.4 | 3.97 | 3.61 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.09 | 0.186 | 1.42 | 2.39 | 1.42 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.175 | 0.271 | 1.48 | 2.43 | 1.44 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 0.402 | 3.41 | 0.917 | 1.54 | 2.17 |
| Total Liabilities & Shareholders' Equity | 0.577 | 3.69 | 2.4 | 3.97 | 3.61 |
| Total Common Shares Outstanding |